Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T05:32:43.002Z Has data issue: false hasContentIssue false

Lipid supplementation in schizophrenia

Published online by Cambridge University Press:  03 January 2018

I. Maurer
Affiliation:
Department of Psychiatry, Friedrich-Schiller University Jena, Philosophenweg 3, 07740 Jena, Germany
H.-P. Volz
Affiliation:
Department of Psychiatry, Friedrich-Schiller University Jena, Philosophenweg 3, 07740 Jena, Germany
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

References

Moser, H. W. (1993) Lorenzo oil therapy for adrenoleukodystrophy: a prematurely amplified hope. Annals of Neurology, 34, 121122.Google ScholarPubMed
Moser, H. W., Moser, A. B., Smith, K. D., et al (1992) Adrenoleukodystrophy: phenotypic variability and implications for therapy. Journal of Inherited Metabolic Disorders, 15, 645664.CrossRefGoogle ScholarPubMed
Poulos, A., Gibson, R., Sharp, P., et al (1994) Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Annals of Neurology, 36, 741746.CrossRefGoogle ScholarPubMed
Walker, N. P., Fox, H. C. & Whalley, L. J. (1999) Lipids and schizophrenia. British Journal of Psychiatry 174, 101104.Google ScholarPubMed
Zinkham, W. H., Kidder, T., Borel, M. S., et al (1993) Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy. New England Journal of Medicine, 328, 11261127.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.